Cidara shares hit 8-year high after Merck's $9.2 bln buyout deal

Cidara Therapeutics

14/11/2025 15:44

Updates

** Shares of Cidara Therapeutics CDTX.O soar 105.28% to $217.5, their highest level in over eight years; Merck MRK.N up 1.02% at $93.88

** Drugmaker Merck MRK.N to acquire Cidara in a nearly $9.2 billion deal; gaining access to an experimental drug for flu prevention

** Under the terms, MRK will pay $221.50/shr in cash for CDTX, a premium of 108.9% to its last closing price of $105.99

** "Merck is getting a great value in Cidara's influenza antiviral drug, CD388, and the entire platform has great potential as well," says Steve Brozak, president of WBB Securities LLC

** Including session's move, YTD while MRK was up ~6%, while CDTX was up ~710%

 (Reporting by Sahil Pandey and Avinash P in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))